COPD — Written Clinical Reasoning

SAQ 1 — Acute Exacerbation Management and Integrated Planning (20 marks, 30 minutes)

Prompt: Outline your immediate and ongoing management of this acute presentation. Include your ventilatory strategy with justification, the specific drug regimens and their evidence base, and your plan for his long-term COPD management once stabilised. [1]

Model Answer

Immediate assessment and problem list (3 marks): [1]

This patient has an acute exacerbation of COPD (Anthonisen Type 1) with acute-on-chronic hypercapnic respiratory failure (pH 7.27, PaCO2 75). His problems are:

1. Acute hypercapnic respiratory failure complicating COPD exacerbation — immediate threat
2. Severe COPD (GOLD 3, Group E) with frequent exacerbation phenotype
3. Cor pulmonale with pulmonary hypertension
4. Osteoporosis (disease- and drug-related)
5. Depression
6. Ongoing tobacco dependence
7. Possible over-treatment with ICS (low eosinophils 0.08 — ICS response unlikely, pneumonia risk) [1]

Ventilatory strategy — controlled oxygen plus NIV (5 marks): [1]

1. Controlled oxygen therapy: He is already on 28% Venturi with SpO2 in the low target range (88-92% for COPD with CO2 retention). Oxygen must be titrated to SpO2 88-92% — NEVER high-flow. Excess oxygen worsens hypercapnia via the Haldane effect (reduced CO2 carriage by oxygenated haemoglobin) and V/Q mismatch (relief of hypoxic vasoconstriction increases shunt).
2. Non-invasive ventilation (BiPAP): This is the critical intervention. His blood gas shows persistent hypercapnic respiratory failure (pH 7.27, PaCO2 75) despite 60 minutes of standard therapy — the established indication for NIV [1]. Plant et al. (Lancet 2000) showed early ward-based NIV halved intubation rates (15% vs 27%) and in-hospital mortality (10% vs 20%). BiPAP settings: IPAP starting at 10-12 cmH2O, titrate up by 2 cmH2O toward 20 cmH2O to reduce PaCO2; EPAP 4-5 cmH2O; FiO2 to maintain SpO2 88-92%. Recheck ABG at 1-2 hours. If pH and PaCO2 improve, continue; if worsening (pH less than 7.25) despite optimised NIV, escalate to ICU for invasive ventilation.
3. Contraindications to NIV are absent: he is rousable and cooperative, haemodynamically stable, able to protect his airway.

Pharmacological management (6 marks): [1]

Long-term management plan once stabilised (4 marks): [1]

1. Optimise inhaled therapy: He is on LAMA + ICS/LABA (effectively triple therapy). His blood eosinophils are low (0.08 x 10^9/L), predicting poor ICS response and real pneumonia risk. Consider ICS withdrawal (switch to LAMA/LABA dual bronchodilation) to reduce pneumonia risk and polypharmacy, unless there is an asthma component. If frequent exacerbations persist on dual bronchodilation, roflumilast 500 mcg daily may be added (indicated for GOLD 3-4 chronic bronchitis phenotype with frequent exacerbations).
2. Pulmonary rehabilitation: Refer within 4 weeks of discharge — reduces readmission, improves dyspnoea, exercise capacity, and quality of life.
3. Long-term oxygen therapy (LTOT): Assess ABG in stable state at 4-6 weeks. If PaO2 less than 55 mmHg (or 55-59 with cor pulmonale — which he has), prescribe LTOT at least 15 hours/day. This is a mortality-reducing intervention (NOTT).
4. Domiciliary NIV: If he has chronic daytime hypercapnia (PaCO2 greater than 50 after recovery) and a history of acute decompensation, home BiPAP improves survival and symptoms.
5. Cor pulmonale: Continue frusemide (monitor electrolytes); oxygen is the primary therapy for the underlying pulmonary hypertension.
6. Smoking cessation: Intensive counselling plus varenicline — the single most important disease-modifying intervention. Must address before any LTOT (fire risk).
7. Vaccinations: Influenza (annual), pneumococcal, COVID-19.
8. Bone health: Continue alendronate; DEXA; minimise oral steroid courses (his osteoporosis is both disease- and treatment-related).
9. Mental health: Continue sertraline; screen for anxiety.
10. BODE index and prognosis: Calculate his BODE score to prognosticate and frame advance care planning [4].

Communication and follow-up (2 marks): [1]

• Explain the diagnosis and rationale for NIV to the patient and family.
• Medication reconciliation and inhaler technique education.
• COPD action plan for early escalation in future exacerbations.
• Advance care planning: discuss prognosis honestly (BODE-guided), goals of care, and ceilings of treatment given his severe disease and frequent admissions. [1]

SAQ 2 — Investigation Interpretation and Severity Stratification (10 marks, 20 minutes)

Prompt: A 65-year-old woman with a 35 pack-year history presents with progressive exertional dyspnoea. Spirometry (post-bronchodilator): FEV1 1.4 L (52% predicted), FVC 2.6 L, FEV1/FVC 0.54. DLCO is 55% predicted. 6-minute walk distance is 220 metres. mMRC dyspnoea grade is 3. BMI is 19. She has had two courses of oral steroids for exacerbations in the past year and one emergency department visit. Interpret her investigations, classify her COPD, and outline the key management decisions. [1]

Model Answer

Spirometric interpretation (2 marks): [1]

• FEV1/FVC 0.54 (less than 0.70) post-bronchodilator confirms persistent airflow obstruction → COPD.
• FEV1 52% predicted places her at GOLD stage 2 (moderate) by airflow limitation severity.
• The reduced DLCO (55%) indicates emphysematous parenchymal destruction (loss of alveolar-capillary surface), distinguishing emphysema from a pure chronic bronchitis phenotype and predicting more rapid decline. [1]

Multidimensional assessment and BODE index (3 marks): [1]

She is highly symptomatic (mMRC 3), functionally limited (6MWD 220 m), cachectic (BMI 19), and a frequent exacerbator (2 moderate exacerbations/year). Her BODE index: [1]

A BODE of 6 predicts a significantly impaired 4-year survival (approximately 50-60%), far worse than FEV1 alone would suggest. This underscores that her prognosis is driven by the systemic burden, not just the FEV1. [1]

GOLD ABE classification (1 mark): [1]

She has had 2 moderate exacerbations in the past year → GOLD Group E (high exacerbation risk), regardless of symptom level. Initial therapy: LAMA + LABA (dual bronchodilation). [1]

Management decisions (4 marks): [1]

1. Pharmacotherapy: Start LAMA/LABA dual bronchodilation. Check blood eosinophils — if at least 300, consider triple therapy (ICS added); if less than 100, avoid ICS (pneumonia risk). Given her exacerbation history, if eosinophils are high and exacerbations persist on dual therapy, escalate to single-inhaler triple therapy (IMPACT trial evidence).
2. Non-pharmacological: Pulmonary rehabilitation (highest dyspnoea benefit of any intervention), smoking cessation (varenicline), vaccination.
3. Assess for hypoxaemia: Check SpO2; if 92% or less, ABG for LTOT assessment (PaO2 less than 55, or 55-59 with end-organ effects → LTOT at least 15 h/day).
4. Comorbidity screening: DEXA (BMI 19, steroid exposure → osteoporosis risk); depression/anxiety screen; cardiovascular risk assessment.
5. Prognostication and advance care planning: Use the BODE score to discuss prognosis and goals of care appropriately. [1]